TwinBeech Capital’s Intellia Therapeutics NTLA Stock Holding History

TwinBeech Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,289	Closed	-$137K	–	748
2025 Q4	$137K	Buy	+15,289	New	+$210K	0.01%	551
2025 Q3	–	Sell	-137,756	Closed	-$1.29M	–	750
2025 Q2	$1.29M	Buy	+137,756	New	+$1.13M	0.03%	381
2024 Q4	–	Sell	-175,023	Closed	-$3.6M	–	832
2024 Q3	$3.6M	Buy	175,023 +75,071	+75%	+$1.73M	0.07%	312
2024 Q2	$2.24M	Buy	+99,952	New	+$2.38M	0.04%	319
2024 Q1	–	Sell	-17,014	Closed	-$519K	–	773
2023 Q4	$519K	Sell	17,014 -82,266	-83%	-$2.36M	0.01%	548
2023 Q3	$3.14M	Buy	99,280 +61,952	+166%	+$2.4M	0.06%	335
2023 Q2	$1.52M	Sell	37,328 -121,951	-77%	-$4.95M	0.03%	412
2023 Q1	$5.94M	Sell	159,279 -5,081	-3%	-$199K	0.12%	214
2022 Q4	$5.73M	Buy	164,360 +67,890	+70%	+$3.23M	0.11%	226
2022 Q3	$5.4M	Buy	+96,470	New	+$5.98M	0.14%	175

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TwinBeech Capital's NTLA Position: Q1 2026 in Review

TwinBeech Capital sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 15,289 shares — an estimated $137K sold.

TwinBeech Capital first reported a position in NTLA in Q3 2022 and held it in 10 quarters. The position peaked at $5.94M in Q1 2023. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

TwinBeech Capital reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
TwinBeech Capital sold 15,289 Intellia Therapeutics shares in Q1 2026, an estimated $137K.
TwinBeech Capital first reported a position in Intellia Therapeutics in Q3 2022 and held it in 10 quarters.
TwinBeech Capital's Intellia Therapeutics position peaked at $5.94M in Q1 2023.
304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.